Table 1.

CYP2D6 diplotypes with activity scores (ASs) and observed frequencies, and five evaluated phenotypic groupings for the prediction of plasma endoxifen metabolizer status.

Diplotype	ASa	N (898)	%	Codeine	TAM1	TAM2	TAM3c	TAM4d
EM/UM	3	18	2.0	UM	UM	UM	UM	UM
EM/EM	2	300	33.4	EM	EM	EM	EM	EM
EM/IM	1.5	168	18.7	EM	IM	EM	EM	EM
EM/∗10b	1.25	60	6.7	–	–	–	IM	EM
EM/PM	1	221	24.6	EM	IM	IM	IM	IM
IM/IM	1	68	7.6	EM	IM	IM	IM	IM
∗10/∗10b	0.5	45	5.0	–	–	–	IM	SM
IM/PM	0.5	73	8.1	IM	IM	PM	IM	SM
PM/∗10b	0.25	19	2.1				PM	SM
PM/PM	0	50	5.6	PM	PM	PM	PM	PM

^aCalculated as sum of allele activities for PM (0), IM (0.5), EM (1), and UM (2) as described in Gaedigk et al. (2008); note, in ROC analyses EM/PM and IM/IM were distinguished assuming activities of 1 and 0.75, respectively. ^bFor adjusted IM phenotype definitions ^∗10 AS was reduced from 0.5 to 0.25 in TAM3 and TAM4. ^cReduced ^∗10 activity with diplotype AS of 1.5–2 (EM), 0.5–1.25 (IM), and 0–0.25 (PM). ^dReduced ^∗10 activity and definition of a slow metabolizer (SM) group with diplotype AS of 1.25–2 (EM), 1 (IM), 0.25–0.5 (SM), and 0 (PM). Diplotype categories: UM, ultra-rapid-; EM, extensive-; IM, intermediate-; SM, slow-; PM, poor- metabolizer; AS, activity score.